8-K - 4D Molecular Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On March 25, 2026, 4D Molecular Therapeutics appointed Kristian Humer as Principal Accounting Officer, succeeding Ashoo Gupta, who continues as Vice President, Finance and Controller.

Key Takeaways

1Kristian Humer appointed as Principal Accounting Officer, effective immediately on March 25, 2026.

2Humer succeeds Ashoo Gupta, who remains with the Company as Vice President, Finance and Controller.

3Humer has served as the Company's Chief Financial Officer and Principal Financial Officer since November 2025.

4Humer brings prior CFO experience at Foghorn Therapeutics and Viridian Therapeutics, and investment banking background at Citigroup.

Current Report Details

Event Type

Management Change

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25,

Management Change

Executive & Director Changes

Kristian Humer

Principal Accounting Officer

Appointed

Effective: 2026-03-25

Ashoo Gupta

Principal Accounting Officer

Succeeded

Effective: 2026-03-25

Exhibits (1)

8-K